SG 9701729-7

IPOS copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 405/14, A61K 31/495 — A1

(11) International Publication Number: WO 96/13499

(43) International Publication Date: 9 May 1996 (09.05.96)

(21) International Application Number: PCT/EP95/04111

(22) International Filing Date: 19 October 1995 (19.10.95)

(30) Priority Data:
94203120.4 27 October 1994 (27.10.94) EP
(34) Countries for which the regional or international application was filed: DE et al.
455,304 31 May 1995 (31.05.95) US

(60) Parent Application or Grant
(63) Related by Continuation
US 455,304 (CON)
Filed on 31 May 1995 (31.05.95)

(71) Applicant (*for all designated States except US*): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): HEERES, Jan [NL/BE]; Leemskuilen 18, B-2350 Vosselaar (BE). BACKX, Leo, Jacobus, Jozef [BE/BE]; Broekstraat 92, B-2370 Arendonk (BE). HENDRICKX, Robert, Jozef, Maria [BE/BE]; Sint-Corneliusstraat 60, B-2340 Beerse (BE). VAN DER EYCKEN, Luc, Alfons, Leo [BE/BE]; Maurice Pottersstraat 12, B-2350 Vosselaar (BE). DE CHAFFOY DE COURCELLES, Didier, Robert, Guy, Gabriël [BE/BE]; Karel Van Nyenlaan 4, B-2340 Beerse (BE).

(74) Agent: DE CORTE, Filip; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B-2340 Beerse (BE).


(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, HU, IS, JP, KE, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TT, UA, UG, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published
With international search report.

(54) Title: APOLIPOPROTEIN-B SYNTHESIS INHIBITORS

(57) Abstract

The present invention provides novel compounds of formula (I), the N-oxides, the stereochemically isomeric forms thereof, and the pharmaceutically acceptable acid addition salts thereof, wherein A and B taken together form a bivalent radical of formula: -N=CH- (a), -CH=N- (b), -CH_2-CH_2- (c), -CH=CH- (d), -C(=O)-CH_2- (e), -CH_2-C(=O)- (f); R^1 is hydrogen, C_{1-6}alkyl, or halo; R^2 is hydrogen or halo; R^3 is hydrogen; C_{1-8}alkyl; C_{3-6}cycloalkyl or C_{1-8} alkyl substituted with hydroxy, oxo, C_{3-6}cycloalkyl or aryl. Het is five- or six membered optionally substituted heterocyclic ring. The use as a medicine, especially as a lipid lowering agent is disclosed as well as pharmaceutical compositions and processes for preparing compounds and compositions.



(I)